Skip to main content

Purdue University and Akston Biosciences Bring “First Dose of Hope” in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer

Millie, a 10-year-old Shetland Sheepdog, is receiving treatment with the anti-cPD-L1 mAb at the Purdue University Veterinary Hospital. She is pictured with Dr. Deborah Knapp, lead veterinarian on the study.
Millie, a 10-year-old Shetland Sheepdog, is receiving treatment with the anti-cPD-L1 mAb at the Purdue University Veterinary Hospital. She is pictured with Dr. Deborah Knapp, lead veterinarian on the study.

Study enrolls dogs with urothelial carcinoma to assess anti-cPD-L1 monoclonal antibody (mAb) safety and efficacy, with potential applications for human treatments.


The Purdue University College of Veterinary Medicine, in partnership with Akston Biosciences Corporation, has initiated the enrollment of dogs with urinary bladder cancer in a clinical trial of a pioneering immunotherapy. The immunotherapy consisting of an anti-cPD-L1 monoclonal antibody (mAb) is designed to target and block the cPD-L1 protein on cancer cells. This, in turn, is expected to enhance the immune system’s ability to attack the cancer cells more effectively to improve outcomes and extend life. The strategic partnership between Purdue and Akston was announced in August after the underlying technology was developed at the College of Veterinary Medicine and the Purdue Institute for Cancer Research (PICR).

Invasive urothelial carcinoma (InvUC), also known as transitional cell carcinoma (TCC), is the most common and aggressive type of urinary bladder cancer in dogs. While it often starts in the bladder, it can also develop in other parts of the urinary tract and can spread to the lymph nodes, lung, liver and other organs. Although the treatment of InvUC has improved over several years, and the quality of life while living with the cancer can be quite good, the cancer is rarely curable. Over time, the cancer typically develops resistance to treatment and progresses.

The trial, which evaluates the safety, pharmacokinetics, and antitumor effects of the mAb, is supported by a National Cancer Institute (NCI) grant involving the PRE-medical Cancer Immunotherapy Network Canine Trials Consortium (PRECINCT) U01 program. The trial is also supported by the Werling Comparative Oncology Research Center (WCORC) at the Purdue University College of Veterinary Medicine, and aligns with Purdue’s One Health initiative to advance university strengths in human, animal plant, and environmental health.

Parallel studies will also be performed to determine the effects of the mAb on the anti-tumor immune responses in the dogs, insights that hold the potential to advance immunotherapy approaches for both canine and human cancer patients.

Millie, a 10-year-old Shetland Sheepdog (Sheltie), is the first dog to receive the anti-cPD-L1 mAb. It was not surprising that Millie developed bladder cancer. According to Deborah W. Knapp, DVM, MS, Director of the WROC, Distinguished Professor of Comparative Oncology and Purdue’s lead veterinarian on the study, there is a threefold to fivefold increased risk in Shetland sheepdogs when compared with the risk in mixed-breed dogs. The team is excited that Millie has the opportunity to benefit from the new therapy.

Akston Biosciences, which holds an exclusive option to license the anti-cPD-L1 mAb, also serves as a Contract Development and Manufacturing Organization (CDMO), developing and producing the antibody at its Beverly, Mass., facility for the trial. Akston’s rich pipeline also contains candidates for conditions in animals for chronic pain, atopic dermatitis and obesity.

For more information or to participate in the trial, please visit the website for the Werling Comparative Oncology Research Center (WCORC) at Purdue at https://vet.purdue.edu/wcorc/clinical-trials/.

Click here to view a complete news release from Akston Biosciences.

Writer(s): PVM News | pvmnews@purdue.edu

Recent Stories

DVM and Veterinary Technology students gain job opportunity insights at fall PVM Career Fair

Purdue Veterinary Medicine's Fall Career Fair brought veterinary and veterinary technology students together with employers on October 30 at the Purdue Memorial Union. Students explored career opportunities, internships and externships while meeting representatives from veterinary practices and organizations.

In Memory: Dr. Mary Beth Leininger (PU DVM ’67)

Purdue Veterinary Medicine remembers Dr. Mary Beth Leininger (DVM 1967), who died November 6, 2026, at age 83. The first woman elected president of the American Veterinary Medical Association, she spent nearly three decades in private practice and held leadership positions in veterinary medicine, industry and education.

“Paws Up” for Kayla Fuqua – brought to you by the PVM Wellness Committee

Kayla Fuqua, the day-shift Emergency and Critical Care receptionist at our veterinary hospital, is this week's Paws Up honoree. A colleague recognized her for supporting clients, coworkers and veterinary students, answering questions and helping her department during busy shifts.

MMAS Symposium at Purdue provides hands-on learning about Medicine of Mammalian and Avian Species

More than 80 participants joined Purdue Veterinary Medicine's 2026 Medicine of Mammalian and Avian Species Symposium on October 31 and November 1. Organized by the Exotic Animal Club, the two-day event combined presentations on exotic animal medicine with hands-on training in parrot handling, rabbit examinations, avian clinical pathology and other specialized topics.

Costumed characters boost Halloween spirits in Lynn Hall

Halloween brought Minions, the Lorax, Super Mario Bros. characters and plenty of other costumes to Purdue Veterinary Medicine. Students, faculty and staff celebrated with costume contests, trick-or-treating and a Halloween dessert competition in Lynn Hall, the Reed ADDL and the Veterinary Hospital.